Heart Failure and Cardiomyopathies

The Heart Failure (HF) and Cardiomyopathies Learning Pathway at ACC.23/WCC provides a comprehensive overview of the latest developments in the field of HF. Over the past year, there have been numerous pharmacologic and device therapy breakthroughs in the treatment of patients with HF, including treatments for HF with preserved ejection fraction, hypertrophic cardiomyopathy and cardiac amyloidosis. Experts will bring attendees up to speed on these developments and focus on the recently updated AHA/ACC/HFSA Guideline for the Management of Heart Failure.

Learn from experts about what is needed to implement the latest in HF management to a broad group of patients and ensure equitable care (Session 653). Explore the device therapies that have revolutionized the treatment of HF with a review of the current landscape of devices (Session 608). In addition, examine the entire journey of the cardiogenic shock patient, starting from diagnosis and ending with advanced decision-making considerations in an interactive game show session (Session 509).

Take part in the HF and Cardiomyopathies Learning Pathway for these exciting, informative sessions and more!

Additional Sessions You Won't Want to Miss:

  • Levelling the Field! Sex Disparities in Heart Failure (Session 730)
  • Total Eclipse of the Heart: Pregnancy and the Failing Heart (Session 609)
  • Nephrology Stopped the Diuretics Again…Renal Considerations in the Management of Heart Failure (Session 624)
American College of Cardiology

© 2022 American College of Cardiology Foundation. Visit ACC.org

Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us